Edwards Lifesciences Corp. closed 21.12% short of its 52-week high of $96.12, which the company reached on March 28th.

Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in ...

Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...

According to Benzinga Pro, Edwards Lifesciences's peer group average for short interest as a percentage of float is 3.89%, which means the company has less short interest than most of its peers. Did ...

Valeo Financial Advisors LLC increased its position in Edwards Lifesciences Co. (NYSE:EW – Free Report) by 11.3% in the fourth quarter, according to the company in its most recent Form 13F filing with ...

Investment analysts at Leerink Partnrs lowered their Q1 2025 earnings per share estimates for shares of Edwards Lifesciences ...

Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS ...

Edwards Lifesciences beat Q4 estimates with $1.39B in sales, driven by growth in TMTT, TAVR, and Surgical. The company ...

We regret to report that long term Edwards Lifesciences Corporation (NYSE:EW) shareholders have had that experience, with the share price dropping 28% in three years, versus a market return of ...

In a report released today, Rick Wise from Stifel Nicolaus maintained a Buy rating on Edwards Lifesciences (EW – Research Report), with a price ...

Edwards Lifesciences Corporation (NYSE:EW) develops medical innovations for heart disease and critical care monitoring. Its ...